I am hoping someone can help me with this. I am curious if anyone knows if DOP testing: A testing method employing dioctyl phthalate aerosol for purpose of leak-testing negative air units is used during mould remediation/abatement is in a facillity. I was hoping I can find it in a reputable mould guideline. Example: Health Canada, CCA Mould Guidelines, New York Mould Guidelines, Manitoba Mould Guidelines, CSA standards for infection control, etc.
I have tried to look in the previously mentioned, but found nowhere stating that during remediation, the negative pressure unit should be TESTED to ensure proper operation.
Can someone please help me find where it states that the negative pressure air units should be tested using a (blank) method, during mould remediation.© BrainMass Inc. brainmass.com September 21, 2018, 9:20 pm ad1c9bdddf - https://brainmass.com/earth-sciences/environmental-policy/negative-pressure-testing-mould-79281
Please see the attached file.
The DOP test procedure can evaluate particle penetration and air flow resistance properties of a variety of filtration materials (e.g. HEPA filters, NIOSH respirators, and filter media). The procedure employs a cold aerosol of dioctyl phthalate (DOP) using a TSI® CERTITEST® Model 8130 Automated Filter Tester. Test articles are challenged with particles of the most penetrating particle size range (0.3 µm). Filtration efficiency measurements can be determined up to 99.999%. Samples can be tested at flowrates up to 90 L/min.
Six months of twice weekly directly observed isoniazid and rifam-picin treatment of latent tuberculosis (TB) infection was implemented to improve the outcome of treatment. A total of 591 infected aborigines without previous tuberculosis or treatment of latent TB infection received twice weekly isoniazid and rifampicin for 6 mo from 1992 to 1995. The outcome was compared with 403 infected aborigines without previous tuberculosis or treatment of latent TB infection who received self-administered isoniazid daily for 1 yr from 1986 to 1989. Of patients, 487 (82%) completed the twice weekly 6-mo regimen compared with 77 (19%) who completed the daily 12-mo regimen. The main reason for incomplete treatment was default. Both groups were followed over a 6-yr period. The rate of tuberculosis in the twice-weekly isoniazid and rifampicin-treated patients was 0.9/1,000 patient-years compared with 9/1,000 patient-years in the daily isoniazid-treated patients. The rate of side effects was higher for directly observed treatment patients, 136/1,000 patient-years of drugs, compared with 39/ 1,000 patient-years for self-administered treatment patients. Life-threatening side effects such as skin allergic reactions and hepatitis were the same in both groups. A regimen of 52 doses of directly observed twice weekly isoniazid and rifampicin is an effective and well-tolerated regimen to improve the outcome of the treatment of latent tuberculosis infection in a population with a high rate of default with daily self-administered isoniazid.
From January 1, 1992 to December 31, 1995 infected aboriginal patients, who were eligible for treatment of LTBI and agreed to start, began DOP with INH and RMP twice weekly for 6 mo. They were followed to December 31, 1997. The dosage for INH was 15 mg/kg to a maximum of 900 mg/d and for RMP was 10 mg/kg to a maximum of 600 mg/d. Prescriptions were written monthly and sent in unit doses to the TB worker living in the community. The TB worker delivered one dose twice weekly to the patient and observed and recorded each dose. A medication audit was obtained from the records of the TB workers, from a count of empty unit doses that were returned monthly to the TB Pharmacy, and from monthly mobile clinic reviews by TB consultants. TB workers were trained by the TB Program nurses, funded by the TB Program, hired by the community, and supervised by the Community Health Nurse. There was close communication with the TB Program nurses through telephone, fax, and mobile clinics.
Compliance was calculated from the ratio doses taken/doses prescribed. Treatment continued for 6 mo or until a minimum of 90% of 52 doses had been taken (range 6-9 mo, mean 6.4 mo). Patients who discontinued treatment of LTBI before completion because they did not wish to continue were classified as decision to quit. If they could not be found for more than 1 mo during treatment they were classified as lost to follow-up. Liver function tests were performed only when there was clinical suspicion or high risk of hepatitis (20).
For comparison with the DOP group, the records of all aboriginal patients who began ...
The negative pressure testing of mould is addressed.